Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trialAlvin F. Wells, Jacob Aelion, Alan Kivitz et al.|Lara D. Veeken|2018Cited by 101
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)Peter Nash, Jacob Aelion, Kamal Ohson et al.|Annals of the Rheumatic Diseases|2018Cited by 88
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysisArthur Kavanaugh, Philip J. Mease, Dafna D. Gladman et al.|Arthritis Research & Therapy|2019Cited by 80
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studiesDafna D. Gladman, Philip J. Mease, Arthur Kavanaugh et al.|RMD Open|2018Cited by 38
Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled TrialsPhilip J. Mease, J. Wollenhaupt, Nikolay Delev et al.|ACR Open Rheumatology|2020Cited by 21